Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies, has announced its participation in the Maxim Group 2024 Virtual Healthcare Summit. The company's CEO, Brian M. Culley, will be featured in a fireside chat hosted by Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group.
The fireside chat is scheduled for Tuesday, October 15, 2024, at 11:00 a.m. ET. It will be available for viewing by registered conference attendees. This event provides an opportunity for Lineage Cell Therapeutics to showcase its progress and discuss its innovative approach to addressing unmet medical needs through allogeneic cell therapies.
Lineage Cell Therapeutics (NYSE American e TASE: LCTX), una compagnia biotech in fase clinica focalizzata sullo sviluppo di terapie cellulari allogeniche, ha annunciato la sua partecipazione al Maxim Group 2024 Virtual Healthcare Summit. Il CEO dell'azienda, Brian M. Culley, sarà presente in una chiacchierata informale condotta da Jason McCarthy, Ph.D., Direttore Gestore Senior e Responsabile della Ricerca Biotecnologica di Maxim Group.
La chiacchierata informale è programmata per martedì 15 ottobre 2024, alle 11:00 ET. Sarà disponibile per la visione da parte dei partecipanti registrati alla conferenza. Questo evento offre a Lineage Cell Therapeutics l'opportunità di mostrare i propri progressi e discutere il suo approccio innovativo per affrontare le esigenze mediche inesplorate attraverso terapie cellulari allogeniche.
Lineage Cell Therapeutics (NYSE American y TASE: LCTX), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias celulares alogénicas, ha anunciado su participación en el Maxim Group 2024 Virtual Healthcare Summit. El CEO de la empresa, Brian M. Culley, será destacado en una charla informal presentada por Jason McCarthy, Ph.D., Director General Senior y Jefe de Investigación en Biotecnología de Maxim Group.
La charla informal está programada para el martes 15 de octubre de 2024, a las 11:00 a.m. ET. Estará disponible para los asistentes registrados a la conferencia. Este evento brinda a Lineage Cell Therapeutics la oportunidad de mostrar sus avances y discutir su enfoque innovador para abordar necesidades médicas no satisfechas a través de terapias celulares alogénicas.
라인에이지 셀 테라퓨틱스 (NYSE 아메리칸 및 TASE: LCTX)는 동종 세포 치료제 개발에 주력하는 임상 단계의 생명공학 회사로, 맥심 그룹 2024 가상 의료 정상 회담에 참여할 것이라고 발표했습니다. 회사의 CEO인 브라이언 M. 컬리는 맥심 그룹의 생명공학 연구 책임자인 제이슨 맥카시 박사가 주최하는 파이어사이드 채팅에 특징으로 소개될 예정입니다.
이 파이어사이드 채팅은 2024년 10월 15일 화요일, 오전 11시 ET에 예정되어 있습니다. 등록된 컨퍼런스 참석자들이 시청할 수 있습니다. 이 행사는 라인에이지 셀 테라퓨틱스가 자신의 진행 상황을 보여주고 동종 세포 치료를 통해 충족되지 않은 의료 요구를 해결하는 혁신적인 접근 방식에 대해 논의할 기회를 제공합니다.
Lineage Cell Therapeutics (NYSE American et TASE: LCTX), une entreprise de biotechnologie en phase clinique focalisée sur le développement de thérapies cellulaires allogéniques, a annoncé sa participation au Maxim Group 2024 Virtual Healthcare Summit. Le PDG de l'entreprise, Brian M. Culley, sera présent lors d'une discussion informelle animée par Jason McCarthy, Ph.D., Directeur Général Senior et Responsable de la Recherche en Biotechnologie chez Maxim Group.
La discussion informelle est prévue pour le mardi 15 octobre 2024, à 11h00 ET. Elle sera accessible aux participants enregistrés à la conférence. Cet événement offre à Lineage Cell Therapeutics l'opportunité de mettre en avant ses progrès et de discuter de son approche innovante pour répondre aux besoins médicaux non satisfaits grâce aux thérapies cellulaires allogéniques.
Lineage Cell Therapeutics (NYSE American und TASE: LCTX), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von allogenen Zelltherapien konzentriert, hat seine Teilnahme am Maxim Group 2024 Virtual Healthcare Summit angekündigt. Der CEO des Unternehmens, Brian M. Culley, wird in einem informellen Gespräch vorgestellt, das von Jason McCarthy, Ph.D., Senior Managing Director und Leiter der Biotechnologieforschung bei Maxim Group, moderiert wird.
Das informelle Gespräch ist für Dienstag, den 15. Oktober 2024, um 11:00 Uhr ET geplant. Es wird für registrierte Teilnehmer der Konferenz verfügbar sein. Diese Veranstaltung bietet Lineage Cell Therapeutics die Gelegenheit, seine Fortschritte zu präsentieren und über seinen innovativen Ansatz zur Deckung unerfüllter medizinischer Bedürfnisse durch allogene Zelltherapien zu diskutieren.
- None.
- None.
About the Maxim Group 2024 Healthcare Virtual Summit
Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management as well as several topical industry panels. For more information on the event and to register, please visit the conference website: https://m-vest.com/events/healthcare-10152024.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, “off-the-shelf,” cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen®, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance™ (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241014461058/en/
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963
Russo Partners – Media Relations
Nic Johnson or David Schull
(Nic.johnson@russopartnersllc.com)
(David.schull@russopartnersllc.com)
(212) 845-4242
Source: Lineage Cell Therapeutics, Inc.
FAQ
When is Lineage Cell Therapeutics (LCTX) presenting at the Maxim Group 2024 Virtual Healthcare Summit?
Who will be representing Lineage Cell Therapeutics (LCTX) at the Maxim Group 2024 Virtual Healthcare Summit?
What type of presentation will Lineage Cell Therapeutics (LCTX) give at the Maxim Group 2024 Virtual Healthcare Summit?
What is the focus of Lineage Cell Therapeutics (LCTX) as a company?
